骨髓增生异常综合征患者感染危险因素及预防

龚婧晔; 肖志坚

doi:10.13201/j.issn.1004-2806.2021.01.015

骨髓增生异常综合征患者感染危险因素及预防

龚婧晔,
肖志坚^,

- 中国医学科学院血液病医院(中国医学科学院血液学研究所)实验血液学国家重点实验室国家血液系统疾病临床医学研究中心(天津, 300020)

详细信息

通讯作者: 肖志坚,E-mail:zjxiao@ihcams.ac.cn

中图分类号: R733

收稿日期: 2020-06-20

Risk factors and prophylaxis of infections in patients with myelodysplastic syndromes

GONG Jingye,
XIAO Zhijian^,

More Information

Corresponding author: XIAO Zhijian, E-mail: zjxiao@ihcams.ac.cn

Received Date: 20 June 2020

摘要

摘要: 骨髓增生异常综合征（myelodysplastic syndromes,MDS）是一组起源于造血干细胞的异质性恶性髓系克隆性疾病^[1]。由于疾病本身及治疗等因素,MDS患者在病程中较易发生感染,感染是MDS患者死亡的主要原因^[2-3]。因此,评估患者感染风险从而及早采取相应监测、预防措施,可进一步改善MDS患者生存质量,延长总体生存时间（overall survival,OS）^[4]。本文就MDS患者的感染危险因素及预防做一综述。
- 骨髓增生异常综合征 /
- 感染 /
- 危险因素 /
- 预防
Abstract: Myelodysplastic syndromes(MDS) are a heterogeneous group of clonal myeloid neoplasms originated from hematopoietic stem cells. Patients with MDS have a relatively high risk of infection due to the disease-related, patient-related and treatment-related factors. Infection remains the most important cause of death in patients with MDS. Therefore, to evaluate and stratify risk for infection and to provide early intensive monitoring and proper prophylaxis strategy can be of important value in improving MDS patients' quality of life and overall survival. In this article, risk factors and prophylaxis of infections in patients with MDS will be reviewed.
- myelodysplastic syndromes /
- infection /
- risk factor /
- prophylaxis

HTML全文

参考文献(42)

[1]	肖志坚.骨髓增生异常综合征的精准诊断与治疗:现况与问题[J].临床血液学杂志,2017,30(5):339-341.
[2]	Dayyani F,Conley AP,Strom SS,et al.Cause of death in patients with lower-risk myelodysplastic syndrome[J].Cancer,2010,116(9):2174-2179.
[3]	Nachtkamp K,Stark R,Strupp C,et al.Causes of death in 2877 patients with myelodysplastic syndromes[J].Ann Hematol,2016,95(6):937-944.
[4]	肖志坚.骨髓增生异常综合征肖志坚2018观点[M].北京:科学技术文献出版社,2018:35-35.
[5]	Neukirchen J,Nachtkamp K,Schemenau J,et al.Change of prognosis of patients with myelodysplastic syndromes during the last 30 years[J].Leuk Res,2015,39(7):679-683.
[6]	Sullivan LR,Sekeres MA,Shrestha NK,et al.Epidemiology and risk factors for infections in myelodysplastic syndromes[J].Transpl Infect Dis,2013,15(6):652-657.
[7]	Fianchi L,Leone G,Posteraro B,et al.Impaired bactericidal and fungicidal activities of neutrophils in patients with myelodysplastic syndrome[J].Leuk Res,2012,36(3):331-333.
[8]	Toma A,Fenaux P,Dreyfus F,et al.Infections in myelodysplastic syndromes[J].Haematologica,2012,97(10):1459-1470.
[9]	Greenberg PL,Tuechler H,Schanz J,et al.Revised international prognostic scoring system for myelodysplastic syndromes[J].Blood,2012,120:2454-2465.
[10]	Merkel D,Filanovsky K,Gafter-Gvili A,et al.Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine:a retrospective multicenter study[J].Am J Hematol,2013,88(2):130-134.
[11]	Ofran Y,Filanovsky K,Gafter-Gvili A,et al.Higher infection rate after 7-compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndrome[J].Clin Lymphoma Myeloma Leuk,2015,15(6):e95-e99.
[12]	Lorenzana N,Avila LF,Alonso S,et al.The impact of antimicrobial prophylaxis in morbidity and infections during azacitidine treatment[J].Ann Hematol,2017,96(11):1833-1840.
[13]	Della Porta MG,Malcovati L,Strupp C,et al.Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome[J].Haematologica,2011,96(3):441-449.
[14]	Starkman R,Alibhai S,Wells RA,et al.An MDS-specific frailty index based on cumulative deficits adds independent prognostic information to clinical prognostic scoring[J].Leukemia,2020,34(5):1394-1406.
[15]	Bullen JJ,Rogers HJ,Spalding PB,et al.Natural resistance,iron and infection:a challenge for clinical medicine[J].J Med Microbiol,2006,55(Pt 3):251-258.
[16]	Smith BD,Mahmoud D,Dacosta-Byfield S,et al.Health care utilization and risk of infection and bleeding among patients with myelodysplastic syndromes with/without transfusions,and with/without active therapy[J].Leuk Lymphoma,2014,55(5):1119-1125.
[17]	Kontoyiannis DP,Chamilos G,Lewis RE,et al.Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation[J].Cancer,2007,110(6):1303-1306.
[18]	Sloand EM,Wu CO,Greenberg P,et al.Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy[J].J Clin Oncol,2008,26(15):2505-2511.
[19]	Komrokji RS,Mailloux AW,Chen DT,et al.A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction[J].Haematologica,2014,99(7):1176-1183.
[20]	Passweg JR,Giagounidis AA,Simcock M,et al.Immunosuppressive therapy for patients with myelodysplastic syndrome:a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99[J].J Clin Oncol,2011,29(3):303-309.
[21]	List A,Dewald G,Bennett J,et al.Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion[J].N Engl J Med,2006,355(14):1456-1465.
[22]	Le Bras F,Sebert M,Kelaidi C,et al.Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience[J].Leuk Res,2011,35(11):1444-1448.
[23]	Fenaux P,Giagounidis A,Selleslag D,et al.A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q[J].Blood,2011,118(14):3765-3776.
[24]	Almeida A,Fenaux P,Garcia-Manero G,et al.Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q):results of a phase 3 trial[J].Leuk Lymphoma,2018,59(9):2135-2143.
[25]	Fenaux P,Mufti GJ,Hellstrom-Lindberg E,et al.Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes:a randomised,open-label,phase III study[J].Lancet Oncol,2009,10(3):223-232.
[26]	Trubiano JA,Dickinson M,Thursky KA,et al.Incidence,etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes[J].Leuk Lymphoma,2017,58(10):2379-2386.
[27]	Schuck A,Goette MC,Neukirchen J,et al.A retrospective study evaluating the impact of infectious complications during azacitidine treatment[J].Ann Hematol,2017,96(7):1097-1104.
[28]	Silverman LR,McKenzie DR,Peterson BL,et al.Further analysis of trials with azacitidine in patients with myelodysplastic syndrome:studies 8421,8921,and 9221 by the Cancer and Leukemia Group B[J].J Clin Oncol,2006,24(24):3895-3903.
[29]	Pomares H,Arnan M,Sanchez-Ortega I,et al.Invasive fungal infections in AML/MDS patients treated with azacitidine:a risk worth considering antifungal prophylaxis?[J].Mycoses,2016,59(8):516-519.
[30]	Steensma DP,Baer MR,Slack JL,et al.Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes:The Alternative Dosing for Outpatient Treatment(ADOPT)Trial[J].J Clin Oncol,2009,27(23):3842-3848.
[31]	Kantarjian H,Issa JP,Rosenfeld CS,et al.Decitabine improves patient outcomes in myelodysplastic syndromes:results of a phase III randomized study[J].Cancer,2006,106(8):1794-1803.
[32]	Ali AM,Weisel D,Gao F,et al.Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen[J].Cancer Med,2017,6(12):2814-2821.
[33]	徐泽锋,秦铁军,张宏丽,等.地西他滨单药与CAG/HAG方案治疗难治性贫血伴有原始细胞增多的疗效和安全性比较[J].中华血液学杂志,2017,38(7):572-577.
[34]	焦蒙,肖志坚.去甲基化药物治疗骨髓增生异常综合征:治疗失败原因及其解决方案[J].临床血液学杂志,2019,32(3):229-233.
[35]	Girmenia C,Candoni A,Delia M,et al.Infection control in patients with myelodysplastic syndromes who are candidates for active treatment:Expert panel consensus-based recommendations[J].Blood Rev,2019,34:16-25.
[36]	Mallet V,van Bömmel F,Doerig C,et al.Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation:recommendations of the 5th European Conference on Infections in Leukaemia(ECIL-5)[J].Lancet Infect Dis,2016,16(5):606-617.
[37]	Ganzel C,Silverman B,Chemtob D,et al.The risk of tuberculosis in cancer patients is greatest in lymphoma and myelodysplastic syndrome/myeloproliferative neoplasm:a large population-based cohort study[J].Leuk Lymphoma,2019,60(3):720-725.
[38]	Maertens JA,Girmenia C,Bruggemann RJ,et al.European guidelines for primary antifungal prophylaxis in adult haematology patients:summary of the updated recommendations from the European Conference on Infections in Leukaemia[J].J Antimicrob Chemother,2018,73(12):3221-3230.
[39]	Lee JH,Lee KH,Lee JH,et al.Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndrome[J].Leuk Res,2011,35(4):499-503.
[40]	Hutzschenreuter F,Monsef I,Kreuzer KA,et al.Granulocyte and granulocyte-macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromes[J].Cochrane Database Syst Rev,2016,2:CD009310.
[41]	Angelucci E,Li J,Greenberg P,et al.Iron Chelation in Transfusion-Dependent Patients With Low-to Intermediate-1-Risk Myelodysplastic Syndromes:A Randomized Trial[J].Ann Intern Med,2020,172(8):513-522.
[42]	Bitterman R,Eliakim-Raz N,Vinograd I,et al.Influenza vaccines in immunosuppressed adults with cancer[J].Cochrane Database Syst Rev,2018,2(2):CD008983.